Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Mbd Co. Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This volume of active prosecution indicates a focused patent strategy. The portfolio is distributed across 2 distinct examiners, which means each of the 2 pending office actions is being reviewed by a different individual at the USPTO.
All current prosecution activity is concentrated within 1 distinct art unit. This concentration suggests that the company's intellectual property remains aligned with a specific sub-discipline of biotechnology. Practitioners should note that 1 distinct art unit often leads to consistent examiner feedback across the portfolio.
The busiest examiner assigned to the portfolio is KALLAL, ROBERT JAMES, who is responsible for 1 busiest examiner pending action. This 1 busiest examiner pending action represents a significant portion of the company's active matters. Understanding the specific preferences of KALLAL, ROBERT JAMES is critical for successful outcomes.
The presence of 2 distinct examiners means each examiner handles exactly one matter. This lack of overlap prevents the use of cross-application precedents with a single individual. Strategy should focus on the specific Biotechnology & Pharmaceuticals standards governing these filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KALLAL, ROBERT JAMES | 1 | 60.0% | +32.4% |
| AUGER, NOAH ANDREW | 1 | 36.4% | +42.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17239118 | SYSTEM FOR EVALUATING SENSITIVITY TO ANTI-CANCER AGENT AND A COMPUTER READABLE MEDIUM STORING PROGRAMS EXECUTING AN EVALUATING METHOD | AUGER, NOAH ANDREW | 8d |
| 18281746 | METHOD AND SYSTEM FOR PREDICTING SUSCEPTIBILITY TO ANTICANCER AGENT | KALLAL, ROBERT JAMES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17239118 | SYSTEM FOR EVALUATING SENSITIVITY TO ANTI-CANCER AGENT AND A COMPUTER READABLE MEDIUM STORING PROGRAMS EXECUTING AN EVALUATING METHOD | AUGER, NOAH ANDREW | 8d |
| 18281746 | METHOD AND SYSTEM FOR PREDICTING SUSCEPTIBILITY TO ANTICANCER AGENT | KALLAL, ROBERT JAMES | — |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18281746 | METHOD AND SYSTEM FOR PREDICTING SUSCEPTIBILITY TO ANTICANCER AGENT | KALLAL, ROBERT JAMES | — | §101§103DP | Non-Final OA | — | Pending | Sep 12, 2023 |
| 17239118 | SYSTEM FOR EVALUATING SENSITIVITY TO ANTI-CANCER AGENT AND A COMPUTER READABLE MEDIUM STORING PROGRAMS EXECUTING AN EVALUATING METHOD | AUGER, NOAH ANDREW | 1687 | §101§112 | Non-Final OA | 8d | Pending | Apr 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial